madman
Super Moderator
Testosterone treatment for hypogonadal men with organ-confined prostate cancer and unequivocal hypogonadism is under scrutiny for its potential association with cancer recurrence. Physicians are cautious due to the testosterone dependence of metastatic prostate cancer. Previous studies lacked clear evidence of unequivocal hypogonadism in men receiving testosterone treatment for treated prostate cancer. The goal of this study was to examine the relationship between testosterone treatment and cancer recurrence in men with unequivocal hypogonadism and organ-confined prostate cancer.
Take-home points:
Take-home points:
- All patients in the study were confirmed to be hypogonadal based on morning testosterone values, with a criterion of <220 ng/dL.
- The majority of men (14 out of 16) had hypogonadism due to recognizable pituitary or testicular causes, meeting the FDA criterion for testosterone replacement.
- The study provided clear documentation of cancer grade, surgical extent, and regular monitoring for a median duration of 5 years.
- The results specifically apply to men who underwent radical prostatectomy and had organ-confined prostate cancer.
- The results do not apply to men with evidence of cancer spread outside the prostate or those treated with radiation.
- The study's limitations include its retrospective nature, a relatively small number of participants, and some individuals being observed for less than 3 years.
- Testosterone treatment of these men did not show biochemical evidence of cancer recurrence.
- Further confirmation from larger studies would support the safety of this treatment for men meeting the specified criteria.
